中文摘要：

目的探讨富含半胱氨酸的分泌性酸性蛋白（SPARC）在乳腺癌组织的表达及其临床意义。方法收集1997年至2008年在我院行根治性手术的255例有完整随访资料的乳腺癌肿瘤组织石蜡标本，采用组织芯片制作和免疫组化方法检测SPARC蛋白在乳腺癌组织中的表达，分析其与临床病理因素及预后的关系。结果乳腺癌组织SPARC蛋白阳性表达率为76．1％，SPARC在乳腺癌组织中的表达与病理类型（P=0．007）及激素受体状态（P=0．034）相关。SPARC是否阳性表达对乳腺癌患者的无病生存时间（DFS）（P=0．451）、总生存时间（OS）（P=0．562）未显示出有统计学差别，亚组分析显示：绝经前SPARC阴性组患者的DFS优于SPARC阳性组患者的DFS，差别有统计学意义（P=0．013）。多因素Cox比例风险回归分析显示SPARC不是浸润性乳腺癌复发及死亡的独立预后因素。结论SPARC蛋白在乳腺癌的发生、发展中起一定作用，它与雌激素受体表达密切相关，可能是影响绝经前乳腺癌预后的重要指标。

英文摘要：

Objective To study the expression of secreted protein acidic and rich in cysteine （SPARC） in breast cancer, and explore its clinical significance. Methods A total of 255 tumor specimens of radical operation for breast cancer were collected in the First Hospital of China Medical University from 1997 to 2008. The expression of SPARC protein in breast cancer tissues was detected by tissue chips and , and its relationship with clinicopathological factors was analyzed. Results The expression rate of SPARC was 76.1% in breast cancer tissues. The positive expression of SPARC protein was related to invasive ductal carcinoma （ P = 0.007 ）, hormone receptor state （P = 0.034）, and ER state （P = 0.040） . There was no significant difference of the disease-free survival （DFS） （P = 0.451 ） or overall survival （OS） （P = 0.562） between breast cancer patients with/without SPARC expression. Subgroup analysis showed that premenopansal DFS is significantly better than that of SPARC positive patients with SPARC negative group DFS （P = 0.013 ）. Multivariate Cox proportional hazard regression analysis showed that SPARC is not recurrence and mortality of independent prognostic factors invasive breast cancer. Conclusion SPARC protein played an important role in the genesis and development of breast cancer, and was closely related with the expression of estrogen receptor, which could be an important index in premeno- pausal breast cancer prognosis.